Hypertrophic drug-induced gingivites aroused a
special interest from the part of researches, if considering
the quite numerous studies devoted to the clinical aspects
and treatment of such pathological gingival manifestations.
In this context, the first observation to be made is the
absence of an unanimous position as to their treatment,
starting from the prophylaxy up to the most recent surgical
techniques. The risk of the manifestation of post-drug
adverse effects influences any decision related to drug
prescription and, finally, to their consumption. Some drugs
are associated with a higher incidence of anomalies in
children. For example, gingival hyperplasia induced by
phenytoin is more frequent in children and adolescents
than in adult persons. An overgrowth of the gingiva may
be observed in more than 50% of the persons receiving
phenytoin (Dilantin)